Urology Times Journal, Jason M. Broderick – April 15, 2021
The PSMA-targeted Radiopharmaceutical 177Lu-PSMA-617 (LuPSMA) is rapidly advancing through the pipeline in metastatic castration-resistant prostate cancer (mCRPC), which is believed to become one of the first PSMA Theranostics approved by the FDA. Scott T. Tagawa, MD, explained.